Cloud-based trial oversight and management solution enables transparency, flexibility and accountability, delivering confidence in clinical trial integrity
PHILADELPHIA, PA – ERT, a leading eClinical solutions provider, including high-quality patient data collection and analysis, today announced a major release of its Insights Cloud trial oversight solution, with features to optimize transparency, flexibility and accountability for clinical trial sponsors and Clinical Research Organization (CROs). Relationships between sponsors and CROs have become more complex as a result of emerging global regulations for implementing effective risk-based quality management strategies. Compliance with international guidelines has become a shared responsibility that requires a more collaborative and transparent working relationship. “While sponsors and CROs are committed to a shared vision, both parties often struggle to achieve a holistic assessment of trial progress,” said Amy Furlong, Executive Vice President of eClinical Insights at ERT. “Insights Cloud provides the central point of truth for trial oversight that works as a foundation for the transparency, flexibility and accountability that are essential to accomplishing shared goals and healthy relationships.” ERT’s Insights Cloud gives sponsors confidence in the integrity of their trials by delivering real-time holistic data views while enabling proactive monitoring of quality and compliance. CROs gain confidence with cutting-edge integration, automation, and data sharing capabilities that enable them to harmonize disparate data streams into meaningful metrics that support repeatable business processes across clients. ERT will demonstrate Insights Cloud for Sponsors and CROs at the
Drug Information Association (DIA) Annual Meeting
, June 27-29 in Philadelphia, PA. DIA Attendees can visit booth #509 to learn how they can achieve their shared goals of improved data quality, optimized processes, and regulatory compliance. For additional information, visit
http://www.ert.com/insights-cloud
.
About ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process. ERT delivers widely deployed solutions in centralized Cardiac Safety, Respiratory, and electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes – and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. For more information see
www.ert.com
. Join ERT on
,
,
YouTube
and
.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.